Nucleic acid products and methods of administration thereof
First Claim
Patent Images
1. An in vivo method for treating cancer in a subject comprising:
- administering to a tumor cell in the subject a non-viral, cell-free composition comprising a synthetic messenger RNA (mRNA) encoding a gene-editing protein capable of creating a single-strand or double-strand break in an immune checkpoint molecule gene, wherein the synthetic mRNA comprises 5-methoxyuridine, andcausing a single-strand or double-strand break in the DNA of the tumor cell, the single-strand or double-strand break being localized to an immune checkpoint molecule gene in the tumor cell in the subject, resulting in the stimulation or enhancement of an immune response in the subject,thereby treating cancer in the subject.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
-
Citations
11 Claims
-
1. An in vivo method for treating cancer in a subject comprising:
-
administering to a tumor cell in the subject a non-viral, cell-free composition comprising a synthetic messenger RNA (mRNA) encoding a gene-editing protein capable of creating a single-strand or double-strand break in an immune checkpoint molecule gene, wherein the synthetic mRNA comprises 5-methoxyuridine, and causing a single-strand or double-strand break in the DNA of the tumor cell, the single-strand or double-strand break being localized to an immune checkpoint molecule gene in the tumor cell in the subject, resulting in the stimulation or enhancement of an immune response in the subject, thereby treating cancer in the subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
Specification